49 results
Page 2 of 3
6-K
EX-4.2
kt1ui5sbyf5 n9n
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
424B5
0pt2 twbibejkj5
8 Sep 20
Prospectus supplement for primary offering
7:31am
6-K
EX-99.1
ug2jd
4 Jun 20
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
6:11am
F-3
EX-4.1
fsf0ezmxk7d
7 Aug 19
Shelf registration (foreign)
8:24am
F-3
EX-4.2
3kuuxcrwdubexni5do7d
7 Aug 19
Shelf registration (foreign)
8:24am
F-3
3k08qzoj d7zif0i
7 Aug 19
Shelf registration (foreign)
8:24am
424B5
lq7ug xtc
7 Aug 19
Prospectus supplement for primary offering
8:18am
6-K
EX-99.1
thnl4tv7do
7 Aug 19
Current report (foreign)
7:21am
6-K
EX-3.1
bg2h01dtgyc xuoxo5tl
20 May 19
Current report (foreign)
5:28pm
6-K
pw8144nt 1qg5
28 Sep 18
Current report (foreign)
8:40am
424B5
ouq1l
20 Jun 18
Prospectus supplement for primary offering
5:32pm
424B5
vlufdd0nkch2gx776
18 Jun 18
Prospectus supplement for primary offering
9:15pm
6-K
EX-99.1
moj39e fvtx
18 Jun 18
ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS
9:17am
6-K
g1qoxh1fckh3azi wzux
7 Jun 17
Current report (foreign)
12:00am
20-F
ys0uldwlpmr4i
21 Apr 17
Annual report (foreign)
12:00am
F-1
EX-3.2
k9agqsv
30 Dec 16
Registration statement (foreign)
12:00am